Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation

INTRODUCTION: Genomic aberrations involving ALK, ROS1 and MET can be driver oncogenes in lung adenocarcinomas. Identification of tyrosine kinase inhibitors (TKIs) with activity against these tumors and of preclinical systems to model response are warranted. METHODS: We analyzed cases with lung adeno...

Cur síos iomlán

Na minha lista:
Sonraí Bibleagrafaíochta
Foilsithe in:Lung Cancer
Main Authors: Jorge, Susan E., Schulman, Sol, Freed, Jason A., VanderLaan, Paul A., Rangachari, Deepa, Kobayashi, Susumu S., Huberman, Mark S., Costa, Daniel B.
Formáid: Artigo
Teanga:Inglês
Foilsithe: 2015
Ábhair:
Article
Rochtain Ar Líne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4724060/
https://ncbi.nlm.nih.gov/pubmed/26791794
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lungcan.2015.10.028
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!

Míreanna Comhchosúla